title: [The impact of different doses of atorvastatin on plasma endothelin and platelet function in acute ST-segment elevation myocardial infarction after emergency percutaneous coronary intervention].
abstract: Objective:To investigate the effects of different doses of atorvastatin on plasma endothelin and platelet function in acute ST-segment elevation myocardial infarction (STEMI) patients after emergency percutaneous coronary intervention(PCI).Methods:A total of 120 patients with acute STEMI treated with emergency PCI were enrolled and randomly divided into 20 mg of atorvastatin treatment group (standard group,n=60), and 40 mg of atorvastatin treatment group (intensive group,n=60). The blood C reactive protein (CRP), blood lipid profiles, plasma endothelin (ET) were measured before atorvastatin treatment and after 7 days of treatment, respectively. The platelet fibrin clot strength induced by ADP (MAADP) was determined by thrombelastography(TEG).Results:Seven days after of atorvastatin treatment, the level of plasma ET in intensive group was significantly lower than that in standard group [(0.49±0.21)pmol/L vs (0.63±0.58)pmol/L,P<0.05]. Moreover, the MAADP in intensive group was significantly decreased compared with the standard group [(38.4±17.4) mm vs (45.7±14.5) mm,P<0.05]. There was a positive correlation between the ET level and MAADP in intensive group after treatment (r=0.378,P<0.05). However, no significantly differences could be viewed in the CRP and LDL-C levels between the two groups (P>0.05).Conclusion:In patients with acute STEMI, early administration of 40 mg atorvastatin after emergency PCI could significantly reduce the vascular endothelial injury, improve endothelial function, and reduce the residual platelet activity.
authors.affiliation: Heart Center, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China.
authors.forename: X R
authors.initials: XR
authors.lastname: Xu
authors.forename: K B
authors.initials: KB
authors.lastname: Li
authors.forename: P
authors.initials: P
authors.lastname: Wang
authors.forename: L
authors.initials: L
authors.lastname: Xu
authors.forename: Y
authors.initials: Y
authors.lastname: Liu
authors.forename: Z S
authors.initials: ZS
authors.lastname: Yang
authors.forename: X C
authors.initials: XC
authors.lastname: Yang
mesh_terms: D000208:Acute Disease; D000368:Aged; D000924:Anticholesteremic Agents / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D000069059:Atorvastatin / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D001792:Blood Platelets; D002097:C-Reactive Protein / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D016232:Endothelins / Q000097:blood / Q000187:drug effects*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000601:surgery*; D062645:Percutaneous Coronary Intervention; D016896:Treatment Outcome
chemical_list: D000924:Anticholesteremic Agents; D016232:Endothelins; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D002097:C-Reactive Protein; D000069059:Atorvastatin